The CEO of One-carbon Tx, Dr Ana Slipicevic, spoke with Yilmaz Biter at BioPitch about her path from oncology research to leading a first‑in‑class clinical program at One‑carbon Therapeutics.

The conversation offers a clear look at the decisions, data, and translational focus shaping the work of this pioneering biotech.

Read the full interview here.